Trial Profile

A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 04 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Obeticholic acid (Primary)
Indications Hepatic fibrosis; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
Focus Adverse reactions; Registrational; Therapeutic Use
Acronyms REGEN; REGENERATE
Sponsors Intercept Pharmaceuticals

Most Recent Events

08 Jun 2024 Final Results from this study, presented at the European Association for the Study of the Liver Congress 2024
11 Feb 2024 This trial has been completed in Sweden (End Date: 15 Sep 2023), according to European Clinical Trials Database record.
11 Jan 2024 This trial has been completed in Hungary,according to the European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com